Last reviewed · How we verify
NCT05662410
Choroidal Morphology Changes After Aflibercept Therapy in Pachychoroid Neovasculopathy
Phase 4 trial testing Three monthly injections of intravitreal aflibercept in Pachychoroid Neovasculopathy in 30 participants. Completed in 26 May 2024.
24 May 2024
Quick facts
| Lead sponsor | Kim's Eye Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 26 December 2022 |
| Primary completion | 24 May 2024 |
| Estimated completion | 26 May 2024 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Three monthly injections of intravitreal aflibercept — full drug profile →
Conditions studied
- Pachychoroid Neovasculopathy — all drugs for Pachychoroid Neovasculopathy →
Sponsor
Kim's Eye Hospital
Who can join
50 and older, any sex, with Pachychoroid Neovasculopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In the present study, investigators attempt to evaluate the short-term, detailed changes in choroidal morphology after three monthly injections of aflibercept in pachychoroid neovasculopathy. The association between these changes and clinical outcomes will be additionally investigated. The primary purpose of this study is to provide reference data regarding the aflibercept-related morphologic changes that implicate structural and functional choroidal alteration, and hence its clinical implications.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05662410
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Kim's Eye Hospital trials
Trials by the same sponsor.
- NCT07187804 — Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization · Phase 4 · not yet recruiting
- NCT06683950 — Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment · Phase 4 · recruiting
- NCT05662943 — Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV · completed
- NCT04655482 — Treat-and-extend Using Aflibercept for Type 3 Neovascularization · Phase 4 · unknown
- NCT04836143 — Eyes That Do Not Meet the Eligibility Criteria of Clinical Trials on Age-Related Macular Degeneration: Proportion of the · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05662410 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kim's Eye Hospital
- Last refreshed: 31 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05662410.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing